CERT logo

Certara, Inc. Stock Price

NasdaqGS:CERT Community·US$1.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

CERT Share Price Performance

US$9.22
-2.29 (-19.90%)
US$13.21
Fair Value
US$9.22
-2.29 (-19.90%)
30.2% undervalued intrinsic discount
US$13.21
Fair Value
Price US$9.22
AnalystConsensusTarget US$13.21

CERT Community Narratives

AnalystConsensusTarget·
Fair Value US$13.21 30.2% undervalued intrinsic discount

Analysts Maintain Certara Price Target as Pharma Sector Recovery and New Developments Drive Outlook

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative

Trending Discussion

Updated Narratives

CERT logo

CERT: Shares Will Benefit From Biosimulation Leadership As Pharma Rebound Emerges

Fair Value: US$13.21 30.2% undervalued intrinsic discount
8 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Adequate balance sheet with moderate growth potential.

1 Risk
3 Rewards

Certara, Inc. Key Details

US$415.6m

Revenue

US$160.2m

Cost of Revenue

US$255.3m

Gross Profit

US$244.5m

Other Expenses

US$10.9m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
0.068
61.44%
2.62%
27.8%
View Full Analysis

About CERT

Founded
2008
Employees
1517
CEO
William Feehery
WebsiteView website
www.certara.com

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines; Chemaxon Compound Registration, that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Recent CERT News & Updates

Recent updates

No updates